Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29492462 | 1.00 | TYR (0.64) | TYRMEN1MAPTKMT2AHSD17B10 | |
| SCHEMBL28837569 | 0.84 | TYR (0.46) | TYRMEN1KMT2ACYP3A4AOC3 | |
| SCHEMBL21830499 | 0.83 | TYR (0.65) | TYRMEN1MAPTKMT2ACYP3A4 | |
| SCHEMBL29492443 | 0.83 | TYR (0.65) | TYRMEN1MAPTKMT2ACYP3A4 | |
| SCHEMBL21830515 | 0.80 | TYR (0.70) | TYRACHECYP1A2CYP2C19 | |
| SCHEMBL29492425 | 0.80 | TYR (0.70) | TYRACHECYP1A2CYP2C19 | |
| SCHEMBL369337 | 0.79 | TYR (1.00) | TYR | |
| SCHEMBL29394395 | 0.79 | TYR (1.00) | TYR | |
| SCHEMBL18815425 | 0.79 | TYR (1.00) | TYR | |
| SCHEMBL51773 | 0.78 | TYR (0.53) | TYRMEN1MAPTKMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4142680-B1 | STABILIZED COSMETIC COMPOSITIONS WITH N, N'-DI-ACETYL CYSTINE | UNILEVER IP HOLDINGS B V (NL) | 2023-10-18 | — | — | EP | disclosed |
| US-11759412-B2 | Personal care compositions with glutathione precursor comprising 4-substituted resorcinols and amino acids | CONOPCO, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20230181433-A1 | PERSONAL CARE COMPOSITIONS WITH GLUTATHIONE PRECURSOR COMPRISING 4-SUBSTITUTED RESORCINOLS AND AMINO ACIDS | CONOPCO, INC., D/B/A UNILEVER (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230165772-A1 | STABILIZED COSMETIC COMPOSITIONS WITH N, N'-DI-ACETYL CYSTINE | CONOPCO, INC., D/B/A UNILEVER (US) | 2023-06-01 | — | — | US | disclosed |
| EP-4142680-A1 | STABILIZED COSMETIC COMPOSITIONS WITH N, N'-DI-ACETYL CYSTINE | Unilever IP Holdings B.V. (NL) | 2023-03-08 | — | — | EP | disclosed |
| US-11596586-B2 | Personal care compositions with glutathione precursor comprising 4-substituted resorcinols and amino acids | CONOPCO, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| US-20220211596-A1 | PERSONAL CARE COMPOSITIONS WITH GLUTATHIONE PRECURSOR COMPRISING 4-SUBSTITUTED RESORCINOLS AND AMINO ACIDS | CONOPCO, INC., D/B/A UNILEVER (US) | 2022-07-07 | — | — | US | disclosed |
| WO-2021219378-A1 | STABILIZED COSMETIC COMPOSITIONS WITH N, N'-DI-ACETYL CYSTINE | UNILEVER IP HOLDINGS B.V. (NL) | 2021-11-04 | — | — | WO | disclosed |
| EP-3558246-B1 | PERSONAL CARE COMPOSITIONS WITH GLUTATHIONE PRECURSOR COMPRISING 4-SUBSTITUTED RESORCINOLS AND AMINO ACIDS | UNILEVER IP HOLDINGS B V (NL) | 2021-10-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11596586-B2 | Personal care compositions with glutathione precursor comprising 4-substituted resorcinols and amino acids | GPX1, GPX4, GCLC | TYR 6/4885MEN1 4391/4885MAPT 1462/4885 |
| US-20220211596-A1 | PERSONAL CARE COMPOSITIONS WITH GLUTATHIONE PRECURSOR COMPRISING 4-SUBSTITUTED RESORCINOLS AND AMINO ACIDS | GPX1, GPX4, GCLC | TYR 6/4885MEN1 4391/4885MAPT 1462/4885 |
| US-20230165772-A1 | STABILIZED COSMETIC COMPOSITIONS WITH N, N'-DI-ACETYL CYSTINE | NAA40, CRAT, NQO1 | TYR 139/4885MEN1 2447/4885MAPT 2728/4885 |
| US-20230181433-A1 | PERSONAL CARE COMPOSITIONS WITH GLUTATHIONE PRECURSOR COMPRISING 4-SUBSTITUTED RESORCINOLS AND AMINO ACIDS | GPX1, GPX4, GCLC | TYR 6/4885MEN1 4391/4885MAPT 1462/4885 |
| US-11759412-B2 | Personal care compositions with glutathione precursor comprising 4-substituted resorcinols and amino acids | GPX1, GPX4, GCLC | TYR 6/4885MEN1 4391/4885MAPT 1462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.